18 April 2019
Visiongain has launched a new pharma report Clinical Trial Supply and Logistics Market Report: Clinical Trial Manufacturing, Clinical Trial Logistics and Distributions, Clinical Trial Supply Chain Management, Clinical Trial Packaging, Clinical Trial Cold Chain Logistics.
Demands for increasingly complex and expensive clinical trials have led drug developers to look to external service providers to source clinical trial materials and deliver them to investigator sites. Demand for biological and orphan drugs will be one of the factors that drive the clinical trial supply and logistics market for pharma. Rising need for cold chain logistics will increase demand for new packaging and monitoring technologies that offer lower-cost solutions, including reusable packaging and phase change materials that allow cooling for more-specific temperature ranges.
The lead analyst of the report commented "Emerging markets offer many benefits for companies looking to conduct clinical trials, including large patient population and lower trial costs. However, these also offer unique challenges in terms of clinical trial logistics. In many of these markets, the infrastructure connecting second and third tier cities is not as developed as that connecting major cities - these destinations are harder to reach, causing delays in distribution of trial materials, possible resulting in product spoilage.
Additionally, passing through or conducting trials at multiple sites within these regions results in having to comply with varying regulatory and import/export standards. Cold chain integrity also varies within these markets, with few distributors offering a complete cold chain network throughout emerging markets. However, Visiongain predicts that improvements will be made in all these areas in the coming decade, simplifying clinical trial logistics in emerging markets and further increasing their appeal as trial destinations."
Leading companies featured in the report include ADAllen Pharma, Almac Group, Amatsigroup, Biocair International Limited, Catalent, DHL, Durbin PLC, FedEx, Fisher Clinical Services, Marken. Movianto, Packaging Coordinators Inc. and other companies.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market.
08 January 2021
The growth can be attributed to the rising prevalence of respiratory diseases, growing awareness for respiratory diseases, and innovations in respiratory and anesthesia devices. However, unfavourable reimbursement policies and lack of patient adherence in respiratory diseases are some of the factors restraining the growth of the anesthesia and respiratory devices market.
07 January 2021
Factors such as rise in the prevalence of the infectious and bacterial diseases and active participation of government in vaccine development are driving the growth of this market. While high cost of vaccine development is the key factor emerging as a growth barrier over years in this market.
07 January 2021
The potential of microbiome-based drugs as novel treatments to address the unmet needs for many diseases has contributed intensively to the rapid emergence of many investors in this area. Currently, no regulatory framework exists and no drugs have received FDA approval. However, there are several preclinical and clinical-stage companies working with various approaches to develop microbiome-based therapies.